Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

Belong to you Life, creators of the “Belonging-Beating Cancer Together” mobile app, the world’s largest social network and browser app for cancer patients, caregivers and healthcare professionals, today announced the completion of the $14 million Series B fundraising round, led by IQVIA (NYSE:IQV), the world’s leading provider of advanced analytics, technology solutions and contract research services. Other participants of the round included Group Ventures and other existing investors

The Company will use funding to advance and expand the World’s Largest Cancer Social Network and the new Belong Patient Engagement Platform (PEP), which is gaining traction among global health providers, payers, and life science companies. PEP is designed to improve patient engagement, education, compliance, satisfaction, self-care coordination and effectiveness. The end-to-end solution provides hyper-personalized and configurable patient engagement tools, navigation and management services for patients, payers, providers and life science companies.

“We are honored with the support and trust of IQVIA and our investors,” said Eliran Malki, co-founder and Chief Executive Officer of Belong. Life: Life “Belong focuses on building the most robust, hyper-personalized and configurable patient engagement and research platform. Starting with Belong-Beating cancer together, we quickly grew to become the world’s largest social network and patient browser cancer app, collaborating with leading and disruptive researchers and market publications. Now, in addition to increasing our global reach for cancer, Belong will bring its capabilities and expertise to additional diseases and stakeholders in order to deliver on the vision we set at the very beginning. “That’s right.

“Our investment in Belong is part of our strategy to identify and accelerate disruptive technologies that can improve healthcare,” said Tal Rosenberg, IQVIA’s Senior Vice President, Global Technology Solutions. “Belong is able to use and complement IQVIA’s solutions to transform patient engagement through its unique patient engagement platform with machine learning and artificial intelligence capabilities. We’re thrilled to work with Belong as they help transition patient engagement from transactions to experience-giving their customers the kind of engagement they want. “That’s right.

About Belonging Life: Life
Founded in 2015 by well-known entrepreneurs Eliran Malki, Irad Deutsch and Ohad Rubin, Belong-Beating Cancer Together is a free patient navigation app that allows cancer patients and their support network to explore and better manage their treatment journey while improving their quality of life. The Belong global community has access to a proprietary Big Data platform and machine learning technology that enables people to connect, receive and share clinical information anonymously and to discuss issues related to their condition in private. The Belong Patient Engagement Platform provides end-to-end solutions for healthcare organizations, including customized and configurable patient engagement tools, navigation and management services. Today, Belong is the world’s largest digital cancer patient platform and has partnerships with leading patient advocacy associations, including the American Cancer Society, the GO2 Lung Cancer Foundation, Colorectal Cancer Canada, as well as a number of healthcare providers and pharmaceutical companies. The company also conducts research, works with leading universities and has published research with the American Society of Clinical Oncology (ASCO) and other organizations.

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Belong.Life/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co

Leave a Reply

Your email address will not be published. Required fields are marked *